Back to Interventions
Substance / Medication

Vorapaxar

SNOMED 708718003UMLS C2974521

Overview

Active Ingredient
vorapaxar
RxNorm CUI
1537034

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Myocardial infarction
Peripheral arterial vascular disease

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Cholesterol

LOINC 2093-3

secondary

Creatine kinase isoenzymes

LOINC 13969-1

primary

Troponin T.cardiac

LOINC 6598-7

primary

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
4
With Results

Recent Trials

Vorapaxar on Thrombin Generation and Coagulability

NCT03207451Phase 4Completed81 enrolled

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

NCT02545933Phase 4Completed130 enrolled

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650Phase 4Completed66 enrolled

Vorapaxar in the Human Endotoxemia Model

NCT02875028Phase 4Completed16 enrolled
View all 4 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials.
Sharma Abhishek, Helft Gérard, Garg Aakash et al. · Int J Cardiol · 2017
PMID: 27810296Meta-Analysis
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
Qamar Arman, Morrow David A, Creager Mark A et al. · Vasc Med · 2020
PMID: 32000630RCT
A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.
Olivier Christoph B, Sundaram Vandana, Chertow Glenn M et al. · J Vasc Access · 2020
PMID: 31774037RCTFull text (PMC)
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
Correa Simon, Bonaca Marc P, Scirica Benjamin M et al. · J Thromb Thrombolysis · 2019
PMID: 30511258RCT
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
Anderson Matt S, Kosoglou Teddy, Statkevich Paul et al. · Clin Pharmacol Drug Dev · 2018
PMID: 28403576RCTFull text (PMC)
Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova Ethan C, Bonaca Marc P, Dellborg Mikael et al. · Eur Heart J Acute Cardiovasc Care · 2017
PMID: 27075924RCT
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg David D, Bonaca Marc P, Braunwald Eugene et al. · Am J Cardiol · 2016
PMID: 26876014RCT
Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca Marc P, Gutierrez J Antonio, Creager Mark A et al. · Circulation · 2016
PMID: 26826179RCT
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects.
Kraft W K, Gilmartin J H, Chappell D L et al. · Clin Transl Sci · 2016
PMID: 27304196RCTFull text (PMC)
PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease.
Rosser G, Tricoci P, Morrow D et al. · J Thromb Thrombolysis · 2014
PMID: 24676931RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X
Interventional Cardiology Physician

Internal Medicine — Interventional Cardiology

NUCC 207RI0011X
Find a Provider

Health Goals

Goals connected through associated conditions

Improve Cardiovascular Fitness

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vorapaxar (substance)
SNOMED CT
708718003
UMLS CUI
C2974521
RxNorm CUI
1537034

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.